DOCUMENT D'INFORMATION ETABLI CONFORMEMENT À L'ANNEXE IX DU REGLEMENT (UE) 2017/1129 DU PARLEMENT EUROPEEN ET DU CONSEIL DU 14 JUIN 2017, TEL QUE MODIFIE

November 25, 2025 16:01 ET | Source: Transgene S.A. Transgene S.A.

DOCUMENT D'INFORMATION ETABLI CONFORMEMENT À L'ANNEXE IX DU REGLEMENT (UE) 2017/1129 DU PARLEMENT EUROPEEN ET DU CONSEIL DU 14 JUIN 2017, TEL QUE MODIFIE

Pièce jointe

2025-Talisman - Annexe IX PP et PrimaryBid (FINAL)

Attachments

2025-Talisman - Annexe IX PP et PrimaryBid (FINAL)...

Recommended Reading

December 17, 2025 11:45 ET | Source: Transgene S.A.

Transgene to Participate in Upcoming Investor Meetings

Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today...
Read More
November 26, 2025 18:15 ET | Source: Transgene S.A.

Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets

Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday,...
Read More